Effects of Intensive Glycemic Control on Clinical Outcomes Among Patients With Type 2 Diabetes With Different Levels of Cardiovascular Risk and Hemoglobin A1c in the ADVANCE Trial.
Jingyan TianToshiaki OhkumaMark CooperStephen HarrapGiuseppe ManciaNeil PoulterJi-Guang WangSophia ZoungasMark WoodwardJohn ChalmersPublished in: Diabetes care (2020)
The major benefits for patients with T2D in ADVANCE did not substantially differ across levels of baseline ASCVD risk and HbA1c.